» Articles » PMID: 9164861

Prolactin Stimulates the JAK2 and Focal Adhesion Kinase Pathways in Human Breast Carcinoma T47-D Cells

Overview
Journal Biochem J
Specialty Biochemistry
Date 1997 May 15
PMID 9164861
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Treatment of T47-D human breast carcinoma cells with recombinant prolactin (rhPRL) induced a concentration- and time-dependent increase in the phosphotyrosine content of JAK2. rhPRL also stimulated JAK2 tyrosine phosphorylation more weakly in three other breast carcinoma lines, MCF-7, ZR-75-1 and MDA-MB-231. Furthermore it stimulated tyrosine phosphorylation of two isoforms of the transcriptional activator STAT5, STAT5a and STAT5b. Surprisingly, rhPRL treatment of T47-D cells also stimulated tyrosine phosphorylation of focal adhesion kinase (FAK), as determined by immunoprecipitation with anti-phosphotyrosine antibody followed by immunoblotting with a specific FAK antibody. The effect of rhPRL was rapid and concentration-dependent, being maximal at 5 ng/ml. At rhPRL concentrations above 25 ng/ml, FAK tyrosine phosphorylation declined but remained above control levels at 100 ng/ml. rhPRL also stimulated paxillin tyrosine phosphorylation in T47-D cells with similar concentration- and time-dependence. In a second human breast carcinoma cell line, MCF-7, rhPRL produced very similar effects on FAK and paxillin tyrosine phosphorylation. These findings identify a new protein tyrosine kinase pathway in the action of the lactogenic hormone rhPRL and represent the first report that a hormone acting through a member of the haemopoietin receptor superfamily can regulate the FAK/paxillin pathway.

Citing Articles

The immunotoxin targeting PRLR increases tamoxifen sensitivity and enhances the efficacy of chemotherapy in breast cancer.

Zhang J, Liu J, Yue Y, Wang L, He Q, Xu S J Exp Clin Cancer Res. 2024; 43(1):173.

PMID: 38898487 PMC: 11188579. DOI: 10.1186/s13046-024-03099-4.


Prolactin: The Third Hormone in Breast Cancer.

Schuler L, OLeary K Front Endocrinol (Lausanne). 2022; 13:910978.

PMID: 35784527 PMC: 9244687. DOI: 10.3389/fendo.2022.910978.


The Relevant Participation of Prolactin in the Genesis and Progression of Gynecological Cancers.

Ramirez-de-Arellano A, Villegas-Pineda J, Hernandez-Silva C, Pereira-Suarez A Front Endocrinol (Lausanne). 2021; 12:747810.

PMID: 34745013 PMC: 8566755. DOI: 10.3389/fendo.2021.747810.


Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models.

Leehy K, Truong T, Mauro L, Lange C J Steroid Biochem Mol Biol. 2017; 176:88-93.

PMID: 28442393 PMC: 5653461. DOI: 10.1016/j.jsbmb.2017.04.011.


Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells.

Barcus C, OLeary K, Brockman J, Rugowski D, Liu Y, Garcia N Breast Cancer Res. 2017; 19(1):9.

PMID: 28103936 PMC: 5244528. DOI: 10.1186/s13058-017-0801-1.


References
1.
Sinnett-Smith J, Zachary I, Valverde A, Rozengurt E . Bombesin stimulation of p125 focal adhesion kinase tyrosine phosphorylation. Role of protein kinase C, Ca2+ mobilization, and the actin cytoskeleton. J Biol Chem. 1993; 268(19):14261-8. View

2.
Zachary I, Rozengurt E . Focal adhesion kinase (p125FAK): a point of convergence in the action of neuropeptides, integrins, and oncogenes. Cell. 1992; 71(6):891-4. DOI: 10.1016/0092-8674(92)90385-p. View

3.
Turner C, Schaller M, Parsons J . Tyrosine phosphorylation of the focal adhesion kinase pp125FAK during development: relation to paxillin. J Cell Sci. 1993; 105 ( Pt 3):637-45. DOI: 10.1242/jcs.105.3.637. View

4.
Weiner T, Liu E, Craven R, Cance W . Expression of focal adhesion kinase gene and invasive cancer. Lancet. 1993; 342(8878):1024-5. DOI: 10.1016/0140-6736(93)92881-s. View

5.
Hildebrand J, Schaller M, Parsons J . Identification of sequences required for the efficient localization of the focal adhesion kinase, pp125FAK, to cellular focal adhesions. J Cell Biol. 1993; 123(4):993-1005. PMC: 2200138. DOI: 10.1083/jcb.123.4.993. View